IP Library › Granted Patent US 10,385,120
Granted Patent B2
US 10,385,120 · App. 13/576,083 · Granted Aug 20, 2019

Molecular complex for targeting antigens towards cells comprising antigens and uses thereof for vaccination

Inventors: Michel Leonetti (Nozay, FR); Alexandra Savatier (Etampes, FR); Adeline Gadzinski (Villeparisis, FR); Jean-Claude Boulain (Palaiseau, FR)
Assignee: Commissariat a l'Energie Atomique
C07K16/18A61K39/39A61K47/64A61K47/6415A61K47/6811C07K16/2833A61K2039/605
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,385,120
App. No.
13/576,083
Granted
Aug 20, 2019
Kind
B2
Abstract

The invention relates to a molecular complex for targeting the antigen towards cells comprising antigens, including at least one antigen associated with at least two ligands of surface molecules of cells comprising antigens, said complex including at least one first ligand of a sulphated sugar of the glycosaminoglycan family and a second ligand of a specific surface molecule of cells comprising antigens, and said first ligand being covalently bonded with said antigen and/or said second ligand.

Claims (13)

1. An isolated immunogenic complex comprising at least one antigen associated with at least two protein or peptide ligands of surface molecules of antigen-presenting cells,

said at least two protein or peptide ligands at least one first ligand of heparan sulfates and one second ligand of a surface molecule specific for antigen-presenting cells,

wherein the first ligand is an isolated peptide consisting of the R domain of diphtheria toxin (SEQ ID NO: 6);

the second ligand is selected from the group consisting of: a BB fragment of Staphylococcus aureus protein A (SEQ ID NO: 4) and a ZZ derivative thereof (SEQ ID NO: 3),

said antigen is a protein or a peptide which is specific for a tumor,

said first ligand is covalently bonded to said antigen and to said second ligand,

said complex does not comprise the full length diphtheria toxin, and

said complex induces an anti-tumor immune response.

2. The immunogenic complex of claim 1 , wherein said second ligand is the BB fragment (SEQ ID NO: 4).

3. An immunogenic or vaccine composition, comprising at least one immunogenic complex of claim 1 , and a pharmaceutically acceptable vehicle.

4. The immunogenic or vaccine composition of claim 3 , comprising an amount of said complex sufficient to reduce tumor growth.

5. The immunogenic complex of claim 1 , which comprises an amount of said antigen sufficient to treat cancer.

6. The immunogenic complex of claim 1 , wherein the second ligand is the ZZ derivative thereof (SEQ ID NO: 3).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2012
From: LEONETTI, MICHEL; SAVATIER, ALEXANDRA; GADZINSKI, ADELINE; BOULAIN, JEAN-CLAUD
To: COMMISSARIAT A L'ENERGIE ATOMIQUE
Reel/Frame 029038/0428 →
Priority Claims (1)
FR 10 00392 · Feb 1, 2010 · national
Continuity (1)
Related Publication 20130195908A1 · Aug 1, 2013